ZA878837B - Method and compositions for reducing neurotoxic injury - Google Patents

Method and compositions for reducing neurotoxic injury

Info

Publication number
ZA878837B
ZA878837B ZA878837A ZA878837A ZA878837B ZA 878837 B ZA878837 B ZA 878837B ZA 878837 A ZA878837 A ZA 878837A ZA 878837 A ZA878837 A ZA 878837A ZA 878837 B ZA878837 B ZA 878837B
Authority
ZA
South Africa
Prior art keywords
compositions
neurotoxic injury
reducing neurotoxic
reducing
injury
Prior art date
Application number
ZA878837A
Other languages
English (en)
Inventor
Dennis W Choi
W Choi Dennis
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of ZA878837B publication Critical patent/ZA878837B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA878837A 1986-11-25 1987-11-25 Method and compositions for reducing neurotoxic injury ZA878837B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/934,733 US4806543A (en) 1986-11-25 1986-11-25 Method and compositions for reducing neurotoxic injury

Publications (1)

Publication Number Publication Date
ZA878837B true ZA878837B (en) 1988-07-27

Family

ID=25465976

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA878837A ZA878837B (en) 1986-11-25 1987-11-25 Method and compositions for reducing neurotoxic injury

Country Status (11)

Country Link
US (1) US4806543A (xx)
EP (1) EP0270290A3 (xx)
JP (1) JP2602253B2 (xx)
KR (1) KR960008234B1 (xx)
AU (1) AU593698B2 (xx)
CA (1) CA1305056C (xx)
HU (1) HU208079B (xx)
IE (2) IE930156L (xx)
IL (1) IL84535A (xx)
PH (1) PH23635A (xx)
ZA (1) ZA878837B (xx)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226800B (it) * 1988-09-16 1991-02-19 Prodotti Formenti Composizioni farmaceutiche orali contenenti sali di destrorfano.
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
WO1991002810A1 (en) * 1989-08-09 1991-03-07 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
WO1991002523A1 (en) * 1989-08-17 1991-03-07 The Children's Medical Center Corporation Glutamatergic amino acid agonists and antagonists
PT95069B (pt) * 1989-08-24 1997-10-31 Searle & Co Processo para a preparacao de (+)-isomeros de derivados de endoetano/endoetanoepoximofinano, uteis como agentes anti-tussicos
EP0424179A3 (en) * 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
US5013540A (en) * 1989-11-30 1991-05-07 Board Of Regents, The University Of Texas System Using NMDA receptor antagonists to reduce damage due to laser treatment
US5229394A (en) * 1990-07-30 1993-07-20 Arch Development Corporation Method for treatment of amyotrophic lateral sclerosis comprising administration of dmp
US5089517A (en) * 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
US5145862A (en) * 1990-08-16 1992-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US6071876A (en) * 1991-04-19 2000-06-06 Children's Medical Center Corporation Method of preventing NMDA receptor complex-mediated neuronal damage
ATE182076T1 (de) * 1991-04-19 1999-07-15 Childrens Medical Center Verfahren zur vorbeugung nmda-rezeptorkomplex- vermittelter neuronaler schäden
DE69219039T2 (de) * 1991-09-03 1997-07-24 Carter Wallace Verwendung von Felbamate zur Herstellung eines Arzneimittels zur Behandlung neuropsychopharmakologischer Störungen
AU651247B2 (en) 1991-09-06 1994-07-14 Mcneilab, Inc. Composition comprising a tramadol material and acetaminophen and its use
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
TW264473B (xx) * 1993-01-06 1995-12-01 Hoffmann La Roche
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
JP3348230B2 (ja) * 1995-03-03 2002-11-20 アルゴス ファーマシューティカル コーポレーション 尿失禁の治療用のデキシトルメトルファン又はデキシトルオルファンの使用
US5935606A (en) * 1995-07-31 1999-08-10 Sagen; Jaqueline Reversing excitotoxic CNS damage by cellular implantation
GB9522176D0 (en) * 1995-10-30 1996-01-03 Iaf Biochem Int Morphinan derivatives having neuroprotective activity
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
JP2001507924A (ja) 1996-07-22 2001-06-19 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション コナントキン類
WO1998003189A1 (en) 1996-07-22 1998-01-29 Cognetix, Inc. Use of conantokins
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
CA2264043A1 (en) 1996-09-27 1998-04-02 Guilford Pharmaceuticals Inc. Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
GB9706753D0 (en) * 1997-04-03 1997-05-21 Pharmacia & Upjohn Spa Aralkoxy-morphinan derivatives
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
HUP0100310A3 (en) * 1997-12-22 2002-11-28 Euro Celtique Sa A method of preventing abuse of opioid dosage forms
CA2314893C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1299104B1 (en) * 2000-02-08 2009-05-13 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
CA2454328C (en) * 2001-07-18 2008-03-18 Christopher D. Breder Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
CA2457361C (en) 2001-08-06 2008-11-04 Christopher Breder Opioid agonist formulations with releasable and sequestered antagonist
EP2425821B1 (en) 2002-04-05 2017-05-10 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
EP1558268A4 (en) * 2002-09-17 2008-09-17 Univ New York METHODS FOR TREATING AGE-RELATED MEMORY ALTERATIONS (AAMI), LIGHT COGNITIVE DEFICITS (MCI) AND DEMENTIA USING CELL CYCLE INHIBITORS
EP2422773A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1750711B1 (en) * 2004-05-12 2016-10-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of inflammatory conditions with morphinans
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
JP2009525343A (ja) * 2006-02-03 2009-07-09 アバニール・ファーマシューティカルズ 鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物
KR20140079441A (ko) 2006-06-19 2014-06-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
WO2009021058A2 (en) * 2007-08-06 2009-02-12 Trinity Labortories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
US20110251229A1 (en) * 2007-10-30 2011-10-13 The Regents Of The University Of Colorado (+)-opioids and methods of use
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100266645A1 (en) * 2007-12-17 2010-10-21 Alfred Liang Pharmaceutical compositions
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
WO2010003963A1 (en) * 2008-07-07 2010-01-14 Euro-Celtique S.A. Use of opioid antagonists for treating urinary retention
JP5886632B2 (ja) 2009-03-10 2016-03-16 ユーロ−セルティーク エス．エイ． オキシコドンおよびナロキソンを含む即時放出医薬組成物
KR20160034352A (ko) 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
PT3200828T (pt) 2014-10-03 2020-10-08 Lachesis Biosciences Ltd Composições intranasais para o tratamento de doenças e distúrbios neurológicos e neurodegenerativos
CN115215801A (zh) 2016-07-04 2022-10-21 雅芳制药公司 氘代右美沙芬的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694010A (en) * 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
GB8600783D0 (en) * 1986-01-14 1986-02-19 Merck Sharp & Dohme N-methyl-d-aspartate receptor antagonists

Also Published As

Publication number Publication date
EP0270290A3 (en) 1992-06-03
AU8148987A (en) 1988-05-26
IL84535A (en) 1992-09-06
KR960008234B1 (ko) 1996-06-21
PH23635A (en) 1989-09-27
IE930156L (en) 1988-05-25
US4806543A (en) 1989-02-21
AU593698B2 (en) 1990-02-15
JPS63170318A (ja) 1988-07-14
EP0270290A2 (en) 1988-06-08
IE62688B1 (en) 1995-02-22
JP2602253B2 (ja) 1997-04-23
IL84535A0 (en) 1988-04-29
HU208079B (en) 1993-08-30
CA1305056C (en) 1992-07-14
HUT54891A (en) 1991-04-29
KR880005932A (ko) 1988-07-21

Similar Documents

Publication Publication Date Title
PH23635A (en) Method and compositions for reducing neurotoxic injury
YU198087A (en) Process for obtaining nor-statine and nor-cyclostatine
EP0244217A3 (en) Process and apparatus
GB2198584B (en) Semiconductor device and method of making the same
EP0250245A3 (en) Method of making soft ice-drink and apparatus for making the same
EP0269287A3 (en) Treating workpieces
GB8726889D0 (en) Machining apparatus
IL84076A0 (en) Striped-channel transistor and method of forming the same
EP0232884A3 (en) Diafiltration apparatus and method
DE3560030D1 (en) Milling process and milling device
GB2170616B (en) Laser-applied treatment apparatus
EP0243773A3 (en) Method and apparatus for forming disc-wheel like formed parts
PH22818A (en) Composition and method for reducing acetaldehyde toxicity
EP0247387A3 (en) Method and device for deburring profiles
ZA872147B (en) Process and device for cooling
GB2186776B (en) Plant-handling method and device
EP0270497A3 (en) Dough-rolling method
EP0263309A3 (en) Bromofluoroethylhypofluorite and process for its preparation
EP0273571A3 (en) Separating-agents composition and method using same
EP0261098A3 (en) Abrasive or abrasive composition and method for producing it
GB2194544B (en) Imidopolysiloxanes and method for making
GB2188073B (en) Rolling apparatus
IE880626L (en) Method for reducing neurotoxic injury
IL82372A0 (en) 2-vinylpenams and process
GB8605160D0 (en) Method